{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:31:20Z","timestamp":1791721880311,"version":"4.3.4"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund\u2002Die nichtalkoholische Fettlebererkrankung (NAFLD) z\u00e4hlt zu den h\u00e4ufigsten Lebererkrankungen in Deutschland. Langfristig besteht das Risiko einer Leberzirrhose und weiterer Folgeerkrankungen. Epidemiologische Studien zur NAFLD in Deutschland liegen kaum vor. Ziel der vorliegenden Arbeit ist eine dezidierte Analyse der administrativen Inzidenz und Pr\u00e4valenz (der diagnostizierten Erkrankungen) im Zeitraum von 2008 bis 2018.<\/jats:p><jats:p>\n          Methodik\u2002Die Grundlage der Analysen bilden GKV-Routinedaten. Es wurden Personen mit durchg\u00e4ngiger Versicherung im Analysejahr sowie im 3-j\u00e4hrigen Vorbeobachtungszeitraum eingeschlossen (1,7\u20132 Mio. Versicherte pro Analysejahr). Erkrankte Personen wurden \u00fcber relevante ICD-10-Codes (K76.0 und K75.8) identifiziert.<\/jats:p><jats:p>\n          Ergebnisse\u2002Im Jahr 2018 wurde bei 4,66\u200a% der Versicherten eine NAFLD-Diagnose gestellt, eine erstmalige Diagnose lag bei 0,87\u200a% vor. Diagnosen einer Fettleberentz\u00fcndung (NASH) waren mit 0,09\u200a% selten. Im Zeitverlauf zeigt sich eine steigende NAFLD-Pr\u00e4valenz, wobei sich die Zahl der j\u00e4hrlich erstmals diagnostizierten Patienten kaum ver\u00e4ndert hat. Bei Vorliegen von Erkrankungen des metabolischen Syndroms war die Wahrscheinlichkeit einer NAFLD signifikant erh\u00f6ht.<\/jats:p><jats:p>\n          Schlussfolgerungen\u2002Es zeigt sich, dass eine NAFLD im \u00e4rztlichen Alltag h\u00e4ufig diagnostiziert wird, auch wenn Daten aus populationsbasierten Untersuchungen eine noch h\u00f6here Pr\u00e4valenz vermuten lassen.<\/jats:p>","DOI":"10.1055\/a-1402-1263","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T23:54:30Z","timestamp":1616543670000},"page":"851-858","source":"Crossref","is-referenced-by-count":3,"title":["Die H\u00e4ufigkeit von diagnostizierten Fettlebererkrankungen (NAFLD) in der deutschen Bev\u00f6lkerung \u2013 Eine Analyse auf der Basis von GKV-Routinedaten"],"prefix":"10.1055","volume":"59","author":[{"given":"Jona T.","family":"Stahmeyer","sequence":"additional","affiliation":[{"name":"Stabsbereich Versorgungsforschung, AOK Niedersachsen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hemmerling","sequence":"additional","affiliation":[{"name":"Stabsbereich Versorgungsforschung, AOK Niedersachsen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Burger","sequence":"additional","affiliation":[{"name":"Stabsbereich Versorgungsforschung, AOK Niedersachsen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveja","family":"Eberhard","sequence":"additional","affiliation":[{"name":"Stabsbereich Versorgungsforschung, AOK Niedersachsen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Krauth","sequence":"additional","affiliation":[{"name":"Center for Health Economic Research (CHERH), Institut f\u00fcr\u00a0Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Medizinische Hochschule Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zeidler","sequence":"additional","affiliation":[{"name":"Center for Health Economic Research (CHERH), Institut f\u00fcr\u00a0Gesundheits\u00f6konomie, Leibniz Universit\u00e4t Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Herr","sequence":"additional","affiliation":[{"name":"Center for Health Economic Research (CHERH), Institut f\u00fcr\u00a0Gesundheits\u00f6konomie, Leibniz Universit\u00e4t Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Weseloh","sequence":"additional","affiliation":[{"name":"Center for Health Economic Research (CHERH), Institut f\u00fcr\u00a0Gesundheits\u00f6konomie, Leibniz Universit\u00e4t Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegbert","family":"Rossol","sequence":"additional","affiliation":[{"name":"Medizinische Klinik, Krankenhaus Nordwest Frankfurt a.\u200aM."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD","volume":"72","author":"J M Paik","year":"2020","journal-title":"Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatol"},{"key":"ref3","first-page":"447","article-title":"Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment","volume":"111","author":"J Wei\u00df","year":"2014","journal-title":"Dtsch Arzteblatt Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: An expanded review","volume":"9","author":"M Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study","volume":"71","author":"D Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"C Estes","year":"2018","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s10620-019-05986-9","article-title":"Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany","volume":"65","author":"C Labenz","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/2050640620944098","article-title":"Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease","volume":"8","author":"L Kaps","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"ref10","first-page":"719","article-title":"Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease","volume":"117","author":"Y Huber","year":"2020","journal-title":"Dtsch Aerzteblatt Int"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study","volume":"2","author":"J O\u2019Hara","year":"2020","journal-title":"JHEP Rep l"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/tri.12950","article-title":"High resource utilization in liver transplantation-how strongly differ costs between the care sectors and what are the main cost drivers?: a retrospective study","volume":"30","author":"L Harries","year":"2017","journal-title":"Transpl Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Q Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"M Blachier","year":"2013","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3748\/wjg.v11.i12.1848","article-title":"Hepatic steatosis is associated with an increased risk of carotid atherosclerosis","volume":"11","author":"H Volzke","year":"2005","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1148\/radiol.2017161228","article-title":"Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging","volume":"284","author":"J-P K\u00fchn","year":"2017","journal-title":"Radiology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.16016","article-title":"Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease","volume":"52","author":"A Canbay","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","first-page":"664","article-title":"Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications","volume":"106","author":"G P Hammer","year":"2009","journal-title":"Dtsch Arzteblatt Int"},{"key":"ref19","first-page":"464","article-title":"[Use of routine data from statutory health insurances for federal health monitoring purposes]","volume":"57","author":"C Ohlmeier","year":"2014","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.jhepr.2020.100168","article-title":"The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care","volume":"2","author":"W P Hofmann","year":"2020","journal-title":"JHEP Rep I"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"C Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/hep4.1428","article-title":"Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol","volume":"3","author":"C Labenz","year":"2019","journal-title":"Hepatol Commun"},{"key":"ref23","first-page":"668","article-title":"[S2k Guideline non-alcoholic fatty liver disease]","volume":"53","author":"E Roeb","year":"2015","journal-title":"Z Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-019-00020-1","article-title":"New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis","volume":"72","author":"N Pydyn","year":"2020","journal-title":"Pharmacol Rep"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dme.13902","article-title":"Projected number of people with diagnosed Type 2 diabetes in Germany in 2040","volume":"36","author":"T T\u00f6nnies","year":"2019","journal-title":"Diabet Med"},{"key":"ref26","volume-title":"Pr\u00e4ventionsbericht","author":"S Bauer","year":"2020"},{"key":"ref27","first-page":"878","article-title":"[Participation in health behaviour change programmes: results of the German Health Interview and Examination Survey for Adults (DEGS1)]","volume":"56","author":"S Jordan","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref28","volume-title":"Prozessorientierter Leitfaden f\u00fcr die Analyse und Nutzung von Routinedaten der Gesetzlichen Krankenversicherung","author":"S Neubauer","year":"2017","edition":"1. Auflage"},{"key":"ref29","first-page":"243","volume-title":"Sekund\u00e4rdatenanalysen","author":"J Zeidler","year":"2012"},{"key":"ref30","volume-title":"Wei\u00dfbuch Adipositas \u2013 Versorgungssituation in Deutschland","author":"S Klein","year":"2016"},{"key":"ref31","first-page":"447","article-title":"[How \u201erepresentative\u201c are SHI (statutory health insurance) data? Demographic and social differences and similarities between an SHI-insured population, the population of Lower Saxony, and that of the Federal Republic of Germany using the example of the AOK in Lower Saxony]","volume":"56","author":"J Jaunzeme","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1402-1263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T13:45:59Z","timestamp":1637588759000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1402-1263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":31,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1402-1263","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}